5 Analyst Upgrades for Thursday: Agios Pharmaceuticals, Nasdaq, and More
ByAinvest
Friday, Nov 21, 2025 4:48 pm ET1min read
AGIO--
MMC--
NDAQ--
PSN--
RCEL--
Top Wall Street analysts have upgraded several top names, including AVITA Medical, Agios Pharmaceuticals, Nasdaq, Marsh & McLennan Companies, and Parsons Corp. BTIG analyst Ryan Zimmerman upgraded AVITA Medical from Sell to Neutral, while Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals from Market Perform to Outperform. Morgan Stanley analyst Michael Cyprys upgraded Nasdaq from Equal-Weight to Overweight, and Barclays analyst Alex Scott upgraded Marsh & McLennan Companies from Equal-Weight to Overweight. William Blair analyst Louie DiPalma upgraded Parsons Corp from Market Perform to Outperform.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet